Sionna Therapeutics, Inc. (SION)
| Market Cap | 1.79B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.27M |
| Shares Out | 45.14M |
| EPS (ttm) | -1.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 393,867 |
| Open | 39.68 |
| Previous Close | 39.21 |
| Day's Range | 38.58 - 41.15 |
| 52-Week Range | 10.97 - 46.46 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 50.13 (+26.62%) |
| Earnings Date | May 6, 2026 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for SION stock is "Strong Buy." The 12-month stock price target is $50.13, which is an increase of 26.62% from the latest price.
News
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Sionna Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing two NBD1 stabilizers for cystic fibrosis, targeting significant unmet need with both add-on and dual combination strategies. Key clinical data from ongoing studies are expected by mid-2026, supported by strong financial resources and a validated predictive assay.
Sionna Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted the strategy to address unmet needs in CF by developing NBD1 stabilizers, with a focus on dual combinations aiming for clinically meaningful improvements in CFTR function. The phase II study is designed for robust mechanistic proof, and future plans include dose-ranging and co-formulation.
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated...
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The summit highlighted a novel approach to CF treatment using NBD1 stabilizers, with key phase 2a and dual combination studies targeting mid-2026 data. The company aims to address unmet needs in a growing $12–17 billion market, supported by strong financials.
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Focused on NBD1 stabilization, the company is advancing two lead programs targeting the F508del mutation in CF, with pivotal data expected mid-2026. Both add-on and dual combination strategies aim to surpass current standards, addressing a $12B+ market and significant unmet need.
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
A differentiated approach to cystic fibrosis targets the NBD1 domain with two main clinical strategies, aiming for superior efficacy and broad patient impact. Strong financials support development through 2028, with pivotal data expected in mid-2026 and a focus on maximizing patient access and commercial opportunity.
Sionna Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant clinical progress was made with NBD1 stabilizers, including phase I completions and the launch of key phase II and combination studies. The team aims to address unmet needs in CF by improving CFTR function and is confident in their assay's predictive power, with pivotal data expected in mid-2026.
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Transcript: Stifel 2025 Healthcare Conference
The team is advancing two NBD1 stabilizers for cystic fibrosis, aiming to improve CFTR function beyond current standards. Key phase IIa and dual combination studies are underway, with data expected mid-2026 and a strong cash position supporting development.
Sionna Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing NBD1-targeted therapies for CF, with two clinical studies (add-on and dual combo) expected to read out in mid-2026. Both programs leverage validated assays and strong financials, aiming to surpass current standards in CFTR function restoration.
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1...
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc...
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Sionna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Significant progress was highlighted in advancing two NBD1 stabilizers for cystic fibrosis, with both compounds exceeding early clinical targets and two phase 2a trials expected to report data by mid-2026. The company is well-funded, targeting a large, growing market, and aims to deliver best-in-class therapies that address major unmet needs.
Sionna Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Two NBD1 stabilizers exceeded Phase 1 targets and are advancing as an add-on and in dual combinations, with key readouts expected mid-2026. The approach targets significant unmet need in cystic fibrosis, aiming for clinical superiority over current standard of care.
Sionna Therapeutics to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 Dosing initiated for SION-451 combined with SION-2...